Cargando…

Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia

OBJECTIVES: To provide an overview of the extent of hyperlipidemia in very high-risk patients, and how lipid-lowering therapy (LLT) is used in a real-world setting. METHODS: In this multicenter observational study, data were collected from LLT-treated patients with stable CHD or an ACS in Saudi Arab...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Sifri, Saud, Al Shammeri, Owayed, Al Jaser, Saleh, Alkhenizan, Abdullah, Shafiurrehman, Atif Bin Shafi, Morcos, Bassem, Wajih, Sameh, Elnahal, Ibrahim, Horack, Martin, Brudi, Philippe, Lautsch, Dominik, Ambegaonkar, Baishali, Vyas, Ami, Baxter, Carl A., Gitt, Anselm K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Saudi Medical Journal 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146262/
https://www.ncbi.nlm.nih.gov/pubmed/29968891
http://dx.doi.org/10.15537/smj.2018.7.22146
_version_ 1783356371849183232
author Al Sifri, Saud
Al Shammeri, Owayed
Al Jaser, Saleh
Alkhenizan, Abdullah
Shafiurrehman, Atif Bin Shafi
Morcos, Bassem
Wajih, Sameh
Elnahal, Ibrahim
Horack, Martin
Brudi, Philippe
Lautsch, Dominik
Ambegaonkar, Baishali
Vyas, Ami
Baxter, Carl A.
Gitt, Anselm K.
author_facet Al Sifri, Saud
Al Shammeri, Owayed
Al Jaser, Saleh
Alkhenizan, Abdullah
Shafiurrehman, Atif Bin Shafi
Morcos, Bassem
Wajih, Sameh
Elnahal, Ibrahim
Horack, Martin
Brudi, Philippe
Lautsch, Dominik
Ambegaonkar, Baishali
Vyas, Ami
Baxter, Carl A.
Gitt, Anselm K.
author_sort Al Sifri, Saud
collection PubMed
description OBJECTIVES: To provide an overview of the extent of hyperlipidemia in very high-risk patients, and how lipid-lowering therapy (LLT) is used in a real-world setting. METHODS: In this multicenter observational study, data were collected from LLT-treated patients with stable CHD or an ACS in Saudi Arabia between 2013 and 2014. Individuals were included if they were >18 years and had a full lipid profile available, recorded either prior to the baseline physician visit (CHD patients) or within 24-hours of admission to hospital (ACS patients). RESULTS: A total of 737 patients were included in the study, 597 with stable CHD and 140 with ACS. Few patients in either group had an LDL-C level of <70 mg/dl, which is advocated for very high-risk patients (24.3% and 11.4%, respectively). The median distances to this value were 19.0 mg/dl (CHD) and 25.0 mg/dl (ACS). Low doses of statins were being utilized (31 and 24 mg/day for CHD and ACS, respectively), with only minimal intensification for the ACS patients after hospital admission (41 mg/day at follow-up). CONCLUSIONS: Achievement of recommended LDL-C levels was poor for patients with stable CHD or an ACS. Statin intensity was low, indicating huge scope for intensifying the treatment of these very high-risk patients.
format Online
Article
Text
id pubmed-6146262
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Saudi Medical Journal
record_format MEDLINE/PubMed
spelling pubmed-61462622018-09-28 Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia Al Sifri, Saud Al Shammeri, Owayed Al Jaser, Saleh Alkhenizan, Abdullah Shafiurrehman, Atif Bin Shafi Morcos, Bassem Wajih, Sameh Elnahal, Ibrahim Horack, Martin Brudi, Philippe Lautsch, Dominik Ambegaonkar, Baishali Vyas, Ami Baxter, Carl A. Gitt, Anselm K. Saudi Med J Original Article OBJECTIVES: To provide an overview of the extent of hyperlipidemia in very high-risk patients, and how lipid-lowering therapy (LLT) is used in a real-world setting. METHODS: In this multicenter observational study, data were collected from LLT-treated patients with stable CHD or an ACS in Saudi Arabia between 2013 and 2014. Individuals were included if they were >18 years and had a full lipid profile available, recorded either prior to the baseline physician visit (CHD patients) or within 24-hours of admission to hospital (ACS patients). RESULTS: A total of 737 patients were included in the study, 597 with stable CHD and 140 with ACS. Few patients in either group had an LDL-C level of <70 mg/dl, which is advocated for very high-risk patients (24.3% and 11.4%, respectively). The median distances to this value were 19.0 mg/dl (CHD) and 25.0 mg/dl (ACS). Low doses of statins were being utilized (31 and 24 mg/day for CHD and ACS, respectively), with only minimal intensification for the ACS patients after hospital admission (41 mg/day at follow-up). CONCLUSIONS: Achievement of recommended LDL-C levels was poor for patients with stable CHD or an ACS. Statin intensity was low, indicating huge scope for intensifying the treatment of these very high-risk patients. Saudi Medical Journal 2018-07 /pmc/articles/PMC6146262/ /pubmed/29968891 http://dx.doi.org/10.15537/smj.2018.7.22146 Text en Copyright: © Saudi Medical Journal http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Al Sifri, Saud
Al Shammeri, Owayed
Al Jaser, Saleh
Alkhenizan, Abdullah
Shafiurrehman, Atif Bin Shafi
Morcos, Bassem
Wajih, Sameh
Elnahal, Ibrahim
Horack, Martin
Brudi, Philippe
Lautsch, Dominik
Ambegaonkar, Baishali
Vyas, Ami
Baxter, Carl A.
Gitt, Anselm K.
Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia
title Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia
title_full Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia
title_fullStr Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia
title_full_unstemmed Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia
title_short Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia
title_sort prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in saudi arabia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146262/
https://www.ncbi.nlm.nih.gov/pubmed/29968891
http://dx.doi.org/10.15537/smj.2018.7.22146
work_keys_str_mv AT alsifrisaud prevalenceoflipidabnormalitiesandcholesteroltargetvalueattainmentinpatientswithstablecoronaryheartdiseaseoranacutecoronarysyndromeinsaudiarabia
AT alshammeriowayed prevalenceoflipidabnormalitiesandcholesteroltargetvalueattainmentinpatientswithstablecoronaryheartdiseaseoranacutecoronarysyndromeinsaudiarabia
AT aljasersaleh prevalenceoflipidabnormalitiesandcholesteroltargetvalueattainmentinpatientswithstablecoronaryheartdiseaseoranacutecoronarysyndromeinsaudiarabia
AT alkhenizanabdullah prevalenceoflipidabnormalitiesandcholesteroltargetvalueattainmentinpatientswithstablecoronaryheartdiseaseoranacutecoronarysyndromeinsaudiarabia
AT shafiurrehmanatifbinshafi prevalenceoflipidabnormalitiesandcholesteroltargetvalueattainmentinpatientswithstablecoronaryheartdiseaseoranacutecoronarysyndromeinsaudiarabia
AT morcosbassem prevalenceoflipidabnormalitiesandcholesteroltargetvalueattainmentinpatientswithstablecoronaryheartdiseaseoranacutecoronarysyndromeinsaudiarabia
AT wajihsameh prevalenceoflipidabnormalitiesandcholesteroltargetvalueattainmentinpatientswithstablecoronaryheartdiseaseoranacutecoronarysyndromeinsaudiarabia
AT elnahalibrahim prevalenceoflipidabnormalitiesandcholesteroltargetvalueattainmentinpatientswithstablecoronaryheartdiseaseoranacutecoronarysyndromeinsaudiarabia
AT horackmartin prevalenceoflipidabnormalitiesandcholesteroltargetvalueattainmentinpatientswithstablecoronaryheartdiseaseoranacutecoronarysyndromeinsaudiarabia
AT brudiphilippe prevalenceoflipidabnormalitiesandcholesteroltargetvalueattainmentinpatientswithstablecoronaryheartdiseaseoranacutecoronarysyndromeinsaudiarabia
AT lautschdominik prevalenceoflipidabnormalitiesandcholesteroltargetvalueattainmentinpatientswithstablecoronaryheartdiseaseoranacutecoronarysyndromeinsaudiarabia
AT ambegaonkarbaishali prevalenceoflipidabnormalitiesandcholesteroltargetvalueattainmentinpatientswithstablecoronaryheartdiseaseoranacutecoronarysyndromeinsaudiarabia
AT vyasami prevalenceoflipidabnormalitiesandcholesteroltargetvalueattainmentinpatientswithstablecoronaryheartdiseaseoranacutecoronarysyndromeinsaudiarabia
AT baxtercarla prevalenceoflipidabnormalitiesandcholesteroltargetvalueattainmentinpatientswithstablecoronaryheartdiseaseoranacutecoronarysyndromeinsaudiarabia
AT gittanselmk prevalenceoflipidabnormalitiesandcholesteroltargetvalueattainmentinpatientswithstablecoronaryheartdiseaseoranacutecoronarysyndromeinsaudiarabia